Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rosiglitazone: seeking a balanced perspective.

× No keyword cloud information.

7 in total

1. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.

Authors: Walter T Ambrosius; Ronald P Danis; David C Goff; Craig M Greven; Hertzel C Gerstein; Robert M Cohen; Matthew C Riddle; Michael E Miller; John B Buse; Denise E Bonds; Kevin A Peterson; Yves D Rosenberg; Letitia H Perdue; Barbara A Esser; Lea A Seaquist; James V Felicetta; Emily Y Chew
Journal: Arch Ophthalmol Date: 2010-03

2. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.

Authors: Zeina A Habib; Leonidas Tzogias; Suzanne L Havstad; Karen Wells; George Divine; David E Lanfear; Jeffrey Tang; Richard Krajenta; Manel Pladevall; L Keoki Williams
Journal: Pharmacoepidemiol Drug Saf Date: 2009-06 Impact factor: 2.890

7. Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches.

Authors: Jan O Friedrich; Joseph Beyene; Neill K J Adhikari
Journal: BMC Res Notes Date: 2009-01-10

7 in total

Rosiglitazone: seeking a balanced perspective.

1. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.

2. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.

Review 3. Rosiglitazone and cardiovascular risk.

Review 4. Skeletal consequences of thiazolidinedione therapy.

Review 5. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies.

6. DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety.

7. Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches.